eligibility_summary
Adults ≥18 with DLBCL (incl PMBCL, HGBCL w/ MYC/BCL2/6, or t-FL) eligible for BEAM/ASCT, chemosensitive (≥PR) ≤60 d, ECOG 0–2/Karnofsky ≥60, adequate renal/hepatic/pulmonary/cardiac/coagulation and counts, negative pregnancy test/contraception. Post-ASCT day +30–90 CR/PR for maintenance, RT allowed ≥2 wks earlier. Exclude CNS lymphoma, investigational agents, prior anti‑CD19 without CD19+, hypersensitivity, active infection/autoimmune dz, effusions, HIV/HBV/HCV, active 2° malignancy, MDS, serious comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I, single-arm (withdrawn before accrual) study in R/R DLBCL testing: 1) Loncastuximab tesirine (Zynlonta), an anti-CD19 antibody–drug conjugate (ADC) delivering a pyrrolobenzodiazepine dimer that induces DNA crosslinking and apoptosis, given with BEAM conditioning and as post-ASCT maintenance. 2) BEAM chemotherapy: carmustine (nitrosourea alkylating agent, DNA crosslinks), etoposide (topoisomerase II inhibitor, DNA strand breaks), cytarabine/Ara-C (antimetabolite cytidine analog, inhibits DNA polymerase and DNA synthesis), melphalan (alkylating agent, DNA crosslinks). 3) Autologous hematopoietic stem cell transplant (procedure) for marrow rescue. Targets/pathways: CD19 on malignant B cells, DNA crosslinking/alkylation, inhibition of DNA synthesis and topoisomerase II–mediated DNA repair, overall cytotoxic ablation of lymphoma before ASCT and maintenance elimination of residual CD19+ cells.